V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10431989 | 10041644 | 1.8 | 79 | null | 2019-06-04 | 2019-06-09 | Cyclophosphamide High Dose | 02 | null | DA | 100912848 |
| 10432022 | 10041645 | 1.82 | 61.6 | Palliative (P) | 2018-11-13 | 2018-11-13 | GEMCITABINE + PACLITAXEL ALBUMIN (ABRAXANE) | 02 | N | SCALOP-2 TRIAL | 100115346 |
| 10432088 | 10041646 | 1.6 | 67.8 | 03 | 2019-01-08 | 2019-01-14 | CAPECITABINE + CISPLATIN + EPIRUBICIN | 02 | N | CISPLATIN + PEMBROLIZUMAB + PEMETREXED | 101810634 |
| 10432090 | 10041647 | 1.65 | 0 | Palliative (P) | null | 2018-08-23 | Rituximab + Venetoclax | N | N | LETROZOLE + PALBOCICLIB | 101138629 |
| 10432265 | 10041648 | 1.66 | 74.8 | Curative (C) | 2020-11-24 | 2020-12-23 | Sorafenib | 02 | N | ISATUXIMAB + POMALIDOMIDE | 101175110 |
| 10432405 | 10041652 | 1.56 | 80 | null | 2021-01-16 | 2021-01-20 | CYTARABINE + DAUNORUBICIN | 02 | null | CYTARABINE + DAUNORUBICIN | 100937159 |
| 10432564 | 10041654 | 1.5 | 77.2 | Palliative (P) | 2019-08-13 | 2019-09-02 | FLUOROURACIL + OXALIPLATIN + PANITUMUMAB | 02 | Y | BEVACIZUMAB | 101577884 |
| 10432618 | 10041656 | 1.83 | 116.7 | 03 | null | 2020-03-01 | VINORELBINE | null | N | IXAZOMIB + LENALIDOMIDE | 101261049 |
| 10432645 | 10041657 | 1.7 | 54.1 | Palliative (P) | 2019-12-11 | 2019-12-11 | Nilotinib | 02 | N | DABRAFENIB | 101397889 |
| 10432730 | 10041661 | 1.67 | 0 | Neo-adjuvant (N) | 2019-06-19 | 2019-06-20 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | FLAIR TRIAL | 100429081 |
| 10432754 | 10041662 | 1.72 | 85.7 | Palliative (P) | 2018-02-28 | 2018-03-05 | Bortezomib + CYCLOPHOSPHAMIDE | null | Y | RIBOCICLIB | 101364169 |
| 10432764 | 10041663 | 1.85 | 61.5 | Neo-adjuvant (N) | 2016-04-29 | 2016-05-27 | Apalutamide | 02 | N | PCV | 101502651 |
| 10432767 | 10041664 | null | null | Palliative (P) | null | 2017-06-10 | CARBOPLATIN + EPIRUBICIN + PACLITAXEL | Y | null | LOMUSTINE | 100276369 |
| 10432816 | 10041666 | 1.69 | 60.1 | Adjuvant (A) | 2020-08-30 | 2020-09-04 | MELPHALAN + THALIDOMIDE | 02 | null | FCR | 101311167 |
| 10432941 | 10041670 | 1.65 | 59.1 | null | 2017-11-30 | 2017-12-14 | FLAIR trial | 02 | N | CISPLATIN + PEMETREXED | 100463696 |
| 10432952 | 10041671 | null | 0 | 03 | 2020-02-07 | 2020-02-28 | MPT | null | N | CVD | 100193112 |
| 10433090 | 10041675 | null | null | 03 | 2019-06-24 | 2019-06-26 | MATRIX (lymphoma) | 02 | null | MELPHALAN | 100706238 |
| 10433098 | 10041676 | 1.8 | 71.15 | Curative (C) | null | 2018-05-23 | CETUXIMAB | 02 | N | CYCLOPHOSPHAMIDE HIGH DOSE | 101550255 |
| 10433116 | 10041677 | null | null | Palliative (P) | 2018-03-11 | 2018-04-02 | null | 02 | null | MELPHALAN | 101635231 |
| 10433120 | 10041678 | 1.59 | 79.1 | Curative (C) | 2016-06-02 | 2016-06-03 | IDELALISIB + RITUXIMAB | 2 | N | IDARUBICIN + METHOTREXATE + VINCRISTINE | 101538191 |
| 10433134 | 10041679 | 1.67 | 84.9 | Palliative (P) | 2018-01-25 | 2018-02-07 | PEG INTERFERON | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 100634860 |
| 10433229 | 10041684 | 1.83 | 55 | Palliative (P) | 2018-03-31 | 2018-04-01 | CHOP R + METHOTREXATE | 02 | N | RADIUM 223 | 100198833 |
| 10433242 | 10041685 | 1.61 | 81.25 | Palliative (P) | 2019-05-29 | 2019-06-11 | ETOPOSIDE | 02 | N | AML18 TRIAL | 101633082 |
| 10433266 | 10041686 | 1.84 | 69.8 | null | 2021-06-19 | 2021-07-01 | Liposomal Doxorubicin 50mg/m2 | 02 | null | METHOTREXATE | 101378340 |
| 10433349 | 10041689 | 1.61 | 35 | null | 2018-09-15 | 2018-09-23 | FEC 100 | 02 | null | BUSULPHAN | 100573943 |
| 10433351 | 10041690 | 1.8 | 80.2 | 03 | 2020-07-26 | 2020-07-26 | null | 02 | N | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 101709030 |
| 10433380 | 10041691 | 1.87 | 64.35 | Curative (C) | 2019-12-19 | 2019-12-21 | Obinutuzumab +CVP | null | N | RIALTO TRIAL | 101727333 |
| 10433453 | 10041693 | 1.82 | 76 | Disease modification (D) | null | 2019-08-22 | Bortezomib + Panobinostat | N | null | APALUTAMIDE | 101346799 |
| 10433457 | 10041694 | 0 | null | null | 2021-12-23 | 2021-12-31 | GemCarbo Days 1+8 | 02 | null | RIALTO TRIAL | 100929500 |
| 10433492 | 10041695 | 1.74 | 102.9 | null | 2019-09-30 | 2019-10-11 | BLEOMYCIN | 2 | N | BRENTUXIMAB | 100155568 |
| 10433785 | 10041697 | 1.85 | 60 | null | 2018-02-07 | 2018-02-17 | METHOTREXATE | 02 | null | APALUTAMIDE | 101088481 |
| 10433911 | 10041700 | 0 | 82.1 | Palliative (P) | 2019-07-16 | 2019-07-22 | Nilotinib | 02 | null | OXALIPLATIN + MDG | 100666104 |
| 10434010 | 10041703 | 1.62 | 79 | Palliative (P) | 2018-04-25 | 2018-04-29 | AXITINIB | 02 | N | ROSCO TRIAL | 101628523 |
| 10434032 | 10041704 | 1.72 | 57 | null | 2022-01-13 | 2022-01-25 | EOX | 02 | null | ATEZOLIZUMAB + NAB-PACLITAXEL | 101197884 |
| 10434091 | 10041705 | 1.71 | 72.6 | Curative (C) | 2018-09-06 | 2018-09-21 | Carbo F | 02 | N | CARBOPLATIN + LIPOSOMAL DOXORUBICIN | 100936114 |
| 10434144 | 10041706 | 1.82 | 88 | Curative (C) | 2019-03-07 | 2019-03-07 | Bevacizumab+Carbo+Pacliaxel | 02 | null | CVD | 100083176 |
| 10434147 | 10041707 | 1.55 | 58 | null | null | 2019-10-26 | Letrozole + Palbociclib | null | null | CISPLATIN + DOCETAXEL + FLUOROURACIL | 101559950 |
| 10434311 | 10041710 | 1.62 | 81 | Palliative (P) | 2018-04-10 | 2018-04-16 | Nilotinib | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + PACLITAXEL | 101351425 |
| 10434359 | 10041711 | 1.46 | 72.6 | 03 | 2021-09-01 | 2021-09-01 | null | 02 | null | LETROZOLE + PALBOCICLIB | 100491118 |
| 10434471 | 10041713 | 1.69 | 70.8 | Palliative (P) | 2020-06-29 | 2020-07-05 | BENDAMUSTINE | 02 | N | CYCLOPHOSPHAMIDE + OBINUTUZUMAB + VINCRISTINE | 101375258 |
| 10434715 | 10041716 | 1.83 | 83.2 | 03 | 2018-08-06 | 2018-09-02 | Etoposide oral | 02 | N | AVELUMAB + AXITINIB | 101251087 |
| 10434732 | 10041718 | 1.77 | 92.1 | null | 2017-11-08 | 2017-12-18 | null | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 101778289 |
| 10434758 | 10041719 | 0 | 61.5 | Curative (C) | 2020-01-15 | 2020-02-06 | Dasatinib | 02 | N | GEMCARBO | 101285554 |
| 10434804 | 10041720 | 1.69 | 90 | Adjuvant (A) | 2019-11-03 | 2019-11-03 | ABVD | 01 | null | SORAFENIB | 101385722 |
| 10434839 | 10041722 | 1.6 | 66.4 | Palliative (P) | 2022-05-11 | 2022-05-11 | CYCLOPHOSPHAMIDE + DOCETAXEL + DOXORUBICIN | 02 | N | CYCLOPHOSPHAMIDE + DOCETAXEL + TRASTUZUMAB | 101658570 |
| 10434921 | 10041725 | 1.76 | null | Palliative (P) | 2016-12-11 | 2016-12-18 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 02 | N | TEMOZOLOMIDE + RT | 101618366 |
| 10434936 | 10041726 | null | null | null | 2021-05-08 | 2021-05-08 | Ixazomib + Lenalidomide | 02 | null | CISPLATIN + RT | 100434802 |
| 10434938 | 10041727 | 1.8 | 69.8 | 03 | 2018-05-14 | 2018-05-16 | Letrozole + Palbociclib | 02 | N | FLUOROURACIL + OXALIPLATIN + PANITUMUMAB | 100844368 |
| 10435010 | 10041729 | 1.85 | 0 | Curative (C) | 2021-08-25 | 2021-09-14 | AFATINIB | 02 | null | RALTITREXED | 100332515 |
| 10435046 | 10041731 | 1.93 | 60.4 | Palliative (P) | 2020-06-23 | 2020-06-23 | Trastuzumab 21 day loading dose | 02 | N | APALUTAMIDE | 100940760 |